|Publication number||US3478146 A|
|Publication date||Nov 11, 1969|
|Filing date||Jan 17, 1968|
|Priority date||Feb 26, 1965|
|Publication number||US 3478146 A, US 3478146A, US-A-3478146, US3478146 A, US3478146A|
|Inventors||Balassa Leslie L|
|Original Assignee||Balassa Leslie L|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (2), Referenced by (42), Classifications (4), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent 3,478,146 WOUND-HEALING CARTILAGE POWDER EXTRACTING PROCESS Leslie L. Balassa, Blooming Grove, N.Y. 10914 No Drawing. Original application Feb. 26, 1965, Ser. No. 435,693, now Patent No. 3,400,199, dated Sept. 3, 1968. Divided and this application Jan. 17, 1968, Ser. No.
Int. Cl. A61k 17/00, 27/80 US. Cl. 424-95 Claims ABSTRACT OF THE DISCLOSURE This application is a second division of my copending application Ser. No. 435,693 filed Feb. 26, 1965, now US. Patent No. 3,400,199 issued Sept. 3, 1968.
It was observed some time ago that the healing of wounds of human patients is inhibited or retarded if the patients were at the same time undergoing cortisone treatment. It was found further that this inhibition of the healing of the wounds could be overcome in some instances by the use of cartilage powder applied locally.
It has also been shown that the healing of wounds has sometimes been accelerated by the use of rather coarse, hand-ground powder of acid-pepsin digested adult bovine tracheal cartilage having maximum particle size of about 400-450 microns. Experiments were carried out on albino Sherman strain female rats. There was observed a maximum average increase in the rate of healing and in the strength of the healed tissues of about 20% over that of the control animals, the control animals being those with wounds untreated.
One of the problems involved in healing wounds has long been recognized as occurring in a primarily closed incision. When a composition is applied to such a wound, any excess in amount of such application at least initially produces a negative efiect, which has sometimes been called the interposition effect. This is the reduction in tensile strength observed when any substance is placed into a primarily closed wound, even in very small amounts. In the test data reported in this specification where the negative results are reported for prior art compositions such as gelatin, talc, collagen, etc., as well as when the compositions of this invention had been deactivated or degraded by one process or another, it appears that a major contributing factor to the negative results has been the interposition effect. Thus, when the active composition of the invention demonstrates any improvement in the rate of wound-healing, it should be remembered that the improvement has occurred in spite of the initial handicap of the interposition effect which must be overcome. Similarly, care must be exercised to avoid the use of excess quantities of the material of the present invention, to reduce the initial interposition effect in topical applications.
Investigation has been made of many compositions in the past, among them chondroitin sulfate, chondromucoprotein, carregheenan and collagen, and in every instance these have yielded no wound-healing effect whatever. Most have given small negative results, probably as a result of the interposition eifect. Other compounds tested 3,478,146 Patented Nov. 11, 1969 including local hyaluronic acid, glucuronic acid, n-acetylglucosamine, and lysozyme were tested for wound-healing activity without significant effect. For example, parenteral injections on rats of the last three named substances were given on the first post-operative day. This time was chosen since it is on this day that injections of a saline extract of the cartilage of this invention have been shown to be effective. The local applications were at the same density as has been employed for such cartilage preparations (2-4 mg./cm. of wound surface), while the parenteral injections were made from 5% solutions and were 2 cc. and 5 cc. in volume. All these tests were without any significant positive result.
I have now found that the particle size of the cartilage used has a surprisingly profound effect on the rate of healing and on the strength of the healed tissues. Not only is the rate of healing increased as: the particle size of the cartilage is decreased, but also the manner or the process by which the cartilage is pulverized and the conditions prevailing during the pulverizing have a profound bearing on the results obtained with the cartilage powder. The effectiveness of the present invention has been demonstrated in comparative tests to be highly superior to results obtained on animals treated with either collagen, carragheenan, chondroitin sulfate, chondromucoprotein, fibrinogen, gelatin, talc, bone flour or systemic d-methionine. I have also found methods of further increasing the wound-healing activity of the effective powders of this invention and methods of reactivating such powders after they have been inadvertently deactivated or otherwise reduced in activity.
Furthermore, I found most unexpectedly that cartilage taken from the partly calcified skeletons (including foetal skeletons) of very young or newly born animals is much more effective in accelerating the healing of wounds than was the case with the bovine tracheal cartilage powder on which previous observations were based, which included substantial quantities of coarse adult cartilage powder. Preferably the young animal is not over six months old.
While the present invention relates preferably to young cartilage, i.e. from young animals or young or newly regenerated cartilage from older animals as reptiles, whether finely divided or not, and cartilage from mature animals in finely divided (average particle size 40 microns or less) particle form, it is to be understood that the invention encompasses such cartilage either the form which would in maturity retain the cartilaginous form or which would in maturity ossify to bone.
The cartilage may be prepared by any suitable means to result in a product which is essentially pure cartilage substance free from adhering tissue, which may have been removed by acid-pepsin or other suitable enzyme treatment, with or without mechanical assistance, or otherwise.
I have succeeded in preparing highly effective extracts by the use of aqueous solutions of materials which are in the pH range of about 6.5 to 10, and preferably between 5 and 8, at the concentrations employed in preparing the extracts. I prefer to use as extraction aids those which are either volatile and therefore can be readily removed from the extract by volatilization such as for example ammonia or ammonium carbonate, or such materials which if remaining in the extract would cause no harm if applied either topically or introduced parenterally. Dialysis may be employed to remove undesired salts or other dialyzable material which may be present. Other extraction aids are urea, sodium citrate, disodium phosphate, trisodium phosphate, sodium formate, sodium chloride, and similar compounds or mixtures of them.
I succeeded in concentrating the extracts and even obtained dry extracts of substantially unimpaired activity and which could be redissolved or diluted back to the original strength with saline solution by concentrating the extracts in vacuum at low temperature or by freeze-drying them. Subjecting the cartilage or the cartilage powder or the extracts of the invention to irradiation by ultra-violet light for a short period of time may increase the activity of the material to a noticeable degree. Irradiation with ionizing radiation such as gamma rays may also increase the activity of the cartilage.
I have found a surprising synergistic effect in the combination of cartilage powder or cartilage extract of the invention with growth hormone. This effect can be observed both in topical and in parenteral applications.
I succeeded in obtaining satisfactory effects through oral administration of suitably pelletized or encapsulated cartilage powder or cartilage extracts of the invention.
The present invention provides dosage units of effective wound-healing quantity of cartilage powder from a young animal, or from a mature animal, having average particle size between about 1 micron and about 40 microns, or a substantial maximum particle size of about 70 microns, incorporated into a clinically acceptable wound-healing carrier vehicle such as unguent, oil, salve, solution, extract, powder, etc. The invention also contemplates methods of enhancing the wound-healing activity of a cartilage powder and of restoring wound-healing activity in substantially inactivated cartilage powder including partially deactivated cartilage powder. Novel methods are also provided whereby finely divided cartilage powder may be stabilized before, during or after the final comminution stage of production thereof. Various techniques for the extraction of active wound-healing components, agents, and compositions from cartilage powder are included within the present invention.
I found that there were very great differences in the activity of the preparations, depending on the method used in their preparation, the auxiliaries or carrier employed, and in the technique of application. For example, the cartilage powder as well as the extract were effective when they weer absorbed or incorporated with surgical gauze which then was applied to the wound and when the same materials were applied by spraying onto the wound. Also, clinically acceptable carrier vehicles for the effective cartilage powder or extract, such as salves based on aqueous gels such as those from alginates, gum tragacanth, gelatin, gluten, casein, polyvinylpyrrolidone, dextran and many others are effective in many applications. They are also convenient to apply especially over large areas such as is the case with burns.
The effective cartilage powder or cartilage extracts suspended in oils such as tung oil, corn oil, olive oil, or linseed oil, may be applied directly to wounds. The oil dispersons may be emulsified in water, forming oil-in-water type emulsions, or conversely, water may be emulsified in the oil dispersions forming water-in-oil type emulsions. The cartilage and cartilage extracts dispersed in aqueous or oil carriers may be applied directly to the wounds by spraying, brushing, by impregnating in bandaging materials or by any other means which makes it possible to bring the cartilage or its extract into intimate contact with the tissues. In the case of parenteral applications the cartilage or cartilage extract preparations may be introduced subcutaneously, intra-muscularly, intravenously, or through suppositories introduced into rectal or other cavities. Cartilage powders dispersed in suitable oils have been successfully administered orally. Cartilage powder may be administered, as orally, in the form of pellets such as tablets or capsules. On the other hand, by incorporating the cartilage powder onto silica gel or other gel forming materials which are capable of coating the stomach walls, the rate of healing of stomach ulcers may be noticeably increased.
The invention has been used with humans in treatment of keloids (hardened scar tissue). The keloid was initially cut out, and resutured in the presence of the calf cartilage powder of the invention. After more than six months periodic observation, the keloid did not reappear and apparently the invention prevented the re-formation of the keloid scar tissue, contrary to the usual experience of frequent recurrence of keloid formation.
The cartilage saline extract of this invention has also demonstrated a marked anti-inflammatory effect. For example, as when introduced parenterally in the areas affected by psoriasis, almost immediate reduction of the inflammation was observed.
The statistical average of scores of tests involving the application of the cartilage of the present invention shows that there were produced increases of over 50% in the tensile strengths of seven-day-old midline abdominal wounds in rats. The increase in wound-healing rate was even further enhanced when a combination of optimal size (between about 10 and about 30 microns average diameter) and optimal age of the cartilage source (calf) were combined, in an average of which cases maximal increase in wound tensile strength substantially higher than 50% was achieved. Wound strength increase averaging 50% results in less likelihood of wound disaster, less likelihood of wound infection, the capability of removing sutures earlier with attendant further lessening of likelihood of infection as well as further acceleration in final wound-healing rate, thereby resulting in earlier discharge of the patient from care and safer post-care experience.
Furthermore, as the cartilage treated wound ages in accordance with the present invention, it does not become a mass of essentially acellular collagen as does the cicatrix of the untreated wound. Instead, it continues to proliferate in humans actively up to 40 days after wound and frequently longer. It does not however, become hypertrophic or keloidal, and, in fact, appears less bulky than the corresponding control wounds. These observations point to the presence of inhibitory activity in the cartilage of the invention, in addition to the acceleratory factor.
The local use of the finely ground calf cartilage powder is of great clinical value in the treatment of nongranulating wounds of 50 different kinds, without untoward effects, either locally or systemically, as demonstrated in application to the primarily closed wounds of 87 human surgical incisions in a wide variety of procedures. There was no immediate or late evidence of antigenicity.
Controlled tensiometric observations in 15 human volunteers utilizing in each instance paired incisions in the same individual with tensiometry from 7 to 14 days after wounding have shown that the wound treated therein locally with the cartilage preparation of the present invention has been so much stronger than the untreated wounds as to exhibit a measured mean positive differential of approximately 50% over the control value.
The cartilage preparations of the present invention have been successfully utilized to accelerate and to improve the healing of the following types of wounds, either by topical application or by injection of saline extract: chemical burns, third degree skin burns, radioactive injury, chest wall, abdominal and other wounds, operative and postoperative wounds, penetrating wounds such as those of thorax and abdomen, ulcers due to arteriosclerosis and to trophic disturbance, uclers of skin, gangrene of skin due to trauma or physical agent or to undetermined cause, dermatitis, lupus erythematosus with ucler, keloids, atopic eczema, parapsoriasis and psoriasis. Other types of wounds also have responded successfully to the cartilage preparations of this invention with improved results. For example, the invention is especially useful in cases involving cortisone or other steroid treatment (known to retard healing) or involving diabetes.
Test Methods: Unless otherwise stated, the effectiveness of the preparations of the examples herein was established in animal tests as described by J. Prudden, G. Nishihara and L. Baker in The Acceleration of Wound Healing with Cartilage-I, Surgery, Gynecology & Obstetrics 283 (1957).
Sherman strain albino female rats were employed in the tests. The preparation consisted of 5.5 centimeter midline abdominal incision under controlled conditions and closed with interrupted through-and-through sutures of No. 000 silk.
The wound tensile strenght at seven days is determined in millimeters of mercury by a modification of the technique of the method illustrated in the publication cited above.
The rat to be tested is killed by an intracardiac injection of paraldehyde or by exposure to toxic fumes such as to deithyl ether. The test is made prior to the onest of rigor mortis. After the sutures have been removed from the wound, a rubber laetx prophylactic pouch is inserted into the peritoneal cavity through a defect made with a Kelly clamp in the apex of the vagina. After the rubber pouch is in place, and the introitus has been snugged firmly (with a hemostat) around the tube leading to the peritoneal cavity, the rotary air pump connected to the pouch is turned on regulating it in such a manner that the air pressure will increase at a rate of 10 millimeters of mercury every five seconds. The pressure at which the wound splits and the pouch extrudes itself (wholly or in part) through the defect is recorded as the tensile strength of the wound. This is also a quantitive measure of the degree of healing or rate of healing achieved .in the experiments.
The following examples illustrate certain present preferred embodiments of the invention, and it is understood that other methods and embodiments within the spirit of the invention may be made without departing from the scope of the appended claims. Parts and ratios are by weight except as otherwise stated.
EXAMPLE 1 Cartilage pebble mill-ground The tracheas of healthy adult beef cattle were removed within 30 to 60 minutes after the animals were slaughtered. The tracheas were then either processed immediately with an acid-pepsin solution or they were frozen to preserve them, in which case the acid-pepsin digestion may be defererd. The tracheas either fresh or previously frozen were then digested for about six hours at 50 C. in an aqueous solution containing 0.6% acetic powder in a laboratory four-quart size porcelain jar mill,
loaded with one-inch size (average) flint pebbles in a weight ratio of l cartilage to 2 pebbles. Dry Ice (CO was then put on top of the mill charge and the mill was 5 kept open for five minutes to allow the CO to displace the air in the mill. The lid of the mill was: then clamped on tight and the mill rotated as is customary in the performance of the grinding operation. The grinding was carried out at about 20 C. for 96 hours. The ground cartilage was screened through a 325 mesh nylon screen, thereby confining the active cartilage powder to particles less than about 40 microns in size, and having average or majority particle size between about 5 and microns.
EXAMPLE 2 Preparation of cartilage extracts in the pebble mill Extracts of cartilage having high wound-healing activity were produced as follows:
The cartilage was acid-pepsin digested as in Example 1, granulated, and then without drying was suspended in the extracting liquid and then transferred into a pebble mill which was charged to 50% of its volume with flint pebbles of average size, one inch diameter. The ratio of the cartilage to extracting liquid was kept to 25 :75. The liquid suspension was charged into the mill in a quantity just suflicient to fill the voids of the pebbles with the top of the pebbles barely covered by the liquid. The air was then purged from the mill with nitrogen and the mill closed. The mill was allowed to run for six hours at between 3 C. and 4 C. which resulted in a medium fine grinding of the cartilage and in the simultaneous extraction of the active Wound-healing agent from the cartilage.
At the end of the six-hour cycle, the mill was emptied, the fluid paste strained free of the pebbles, the fluid transferred into a centrifuge operated at 6000 r.p.m. and at a temperature of between 3 C. and 4 C. After onehalf hour the centrifuge was stopped and the supernatant liquid strained through a 400 mesh nylon screen. If the strained extract was cloudy, it was returned to the centrifuge and the centrifuging repeated until a clear slightly opalescent extract was obtained.
The extracts were stored at 4 C. preserved with 1:10,000 sodium ethyl mercuri thiosalicylate.
The following extracts were thus prepared:
Total solids of clear extract by weight Cartilage source Extracting liquid percent a Bovine tracheal. Distilled Water 1. 3
d Isotonic saline sol.
Ammonia (28%) 1% 2% urea in water 1% ammonium carbonate in wat 1% dlSOdilJIfl phosphate in water 3% sodium citrate in water. 1% sodium tormate in Water o lo 3% sodium citrate in water 1 p Calf 1 day old Isotonic saline solution q .do 1% ammonia (28%) in water r ..d0 Isotignsic saline solution plus ammonia to 8 2 NorE.-The isotonic saline solution was prepared with distilled water and contained 0.9% NaCl.
acid (U.S.P. glacial) and 0.3% pepsin (N.F. IX grade, 3500 activity) After digestion the tracheal cartilage was removed from the acid-pepsin solution, washed first with water of about C. and then with water of about 25 C. until the eflluent wash water showed no trace of pepsin or acetic acid. The cartilage was dried in vacuum 20 mm. mercury at C. The dried cartilage was defatted by extracting it with a solvent, such as hexane. It was then granulated.
The granulated purified cartilage was ground to a fine 7 EXAMPLE 3 Spray-drying cartilage extracts Dry concentrates were prepared from cartilage extracts as follows:
A laboratory Bowen type spray-dryer was used with the following modifications. In place of the oil furnace, electric heating coils were used to supply the heat energy necessary for the evaporation of the volatile portions of the extracts. Instead of air, nitrogen was used for the hot gas. A vaned disc, rotating at about 20,000 rpm. was used to atomize the extracts. The inlet gas temperature was held to about 280 F., the outlet temperature was between 140 F. and 160 F. The dryer was used as a closed system dryer with the exclusion of oxygen to avoid degrading the active material during the evaporation of the water.
The following dry extracts were thus produced.
Extract used (example) Solids, percent Yield, percent The solids percent means percent of solids in the extracting liquid as determined by drying at 100 C. for two hours.
Yield percent means the dry solids percent obtained from the liquid by the drying process.
The spray-dried powders were stored in tightly closed glass jars in a refrigerator at 4 C.
EXAMPLE 4 Cartilage extracts applied to wound by swabbing to 5.75 cm. longitudinal midline abdominal incision of the female rat.
EXAMPLE 5 The effect of parenterally injected cartilage extracts on the healing of wounds. In each case 5 cc. of the extract was injected into the subcutaneous tissue on the rats back within 24 hours after the abdominal incision.
Rate of wound Cartilage extract (liquid) healing (percent) EXAMPLE 6 This example demonstrates the effect of parenterally injected cartilage extracts combined with a bovine growth hormone. In each case 5 cc. of the extract was mixed with 10 mgm. of a bovine growth hormone, distributed by the Endocrinology Study Section of the National Institutes of Health through the pituitary hormone distribution program. Approximate assay of the growth hormone:
Adenocorticotrophic hormone0.06 U.S.P. milliunit/ mgm.;
Prolactin-0.1 International unit/mgm;
Vasopressin0.0l U.S.P. unit/mgm;
Thyreotrophic hormone-0.008 U.S.P. unit/mgm.;
Oxytocin0.008 U.S.P. unit/mgm.;
Test animals and wounds are as stated in Example 5.
Rate of wound healing (per- Cartilage extract (liquid) cent) 1 None, isotonic saline, control 2 None, isotonic saline with growth hormone control 108 3 Example 2a with growth hormone 110 4 Example 2-b with growth hormon 5 Example 2-i with growth hormone 6 Example 2-i with growth hormone- 135 7. Example 2-1 with growth hormone 8 Example 2-p with growth hormone. 145
9 Example 2-r with growth hormone 148 EXAMPLE 7 This example demonstrates the value of intravenous injections of cartilage extracts or solutions of dried extracts in the healing of wounds. These were made on dogs with circular incisions. Wounds were not sutured but protected only with sterile dressing. The rate of healing was measured by observing the degree of granulation as compared with the control.
Rate of wound Extract healing (percent) EXAMPLE 8 This example demonstrates the effect of applying liquid cartilage extracts on open wounds. Porous fabric, i.e. surgical gauze was saturated with the extracts and applied to the open and unsutured wounds while still wet. Tests were made on dogs. The rate of healing was measured by the observed degree of granulation.
Rate of wound Cartilage extract healing (percent) None, isotonic salin e, control Example 2-r EXAMPLE 9 This example demonstrates the effect of applying dried cartilage extract on open wounds. Porous fabric, i.e. surgical gauze, was saturated with the extracts, dried to a moisture content of about 5% at 30 C. and at a pressure of 50 mm. mercury. The dried gauze was applied to the open and sutured wounds. Tests and observations were as in Example 8.
tenders, such as whole blood, blood plasma, and a plasma substitute, namely, polyvinylpyrrolidone or dextran. Tests were made on dogs. In carrying out these tests 100 cc. blood was taken from the animal and treated as follows:
(I) The blood was mixed with 10 cc. cartilage extract and reinjected into the same animal.
(II) The plasma was obtained from the blood mixed with 10 cc. cartilage extract and reinjected into the same animal from which the blood was obtained.
(III) The blood was replaced by an equal volume of an isotonic aqueous saline solution of polyvinylpyrrolidone 3.5%, viscosity grade K-30 and 10 cc. of a cartilage extract.
The control animals were treated as follows:
Rate of healing Test Cartilage Extract Test as per- (percent) 1 None, control 1 100 2-.- None, control 2... 90 3. 85 4- 130 5... Example 2b.. 125 6. Example 2-b. .III 120 7 Example 2-1. 150 8. Example 2-1. 145 130 150 145 135 The animals used in these experiments weighed not less than 30 lbs. each.
EXAMPLE 11 Forty wounds involving a wide spectrum of human chronic non-healing types of ulcers were treated according to the present invention.
The types of wounds treated were as follows:
No. of wounds (1) Chronic varicose ulcer on bedrest or after surgical correction of venous incompetency 16 (2) Chronic non-healing ulcers of the abdomen following wound disruption in cachectic patients with inoperable carcinoma 6 (3) Radiation ulcer 1 (4) Ulcers of the extremities in chronic ulcerative colitis (gangreneous pyoderma) 2 No. of wounds (5 Non-healing perineal defects in individuals having undergone total colectomy for chronic ulcerative colitis (not on steroids) (6) Non-healing chest wall defect following necrosis of flaps in radical mastectomy 1 (7) Ulcers of the extremities in patient with systemic lupus erythematosus on massive steroid therapy 4 There was no particular sex or age distribution except that all were adults and none was older than 60 or younger than 25 years of age.
In each instance the local therapy was:
At the time of the dressing, the wound was thoroughly cleansed with hydrogen peroxide, and washed with alcohol. It was dried with gauze. The cartilage preparation was applied by atomizing the powder onto the surface and into the wound. In 38 of the 40 cases this treatment resulted in the transformation of the wound surface from a non-granulating, sluggish, dirty grey surface to a typical pink, healthy granulating bed within ten days. In the other two cases a somewhat longer time was required.
EXAMPLE 12 The cartilage powder of the invention was atomized into 83 surgical wounds in 39 human patients with 47 operations, as follows:
CARTILAGE POWDER INSTILLA'IION IN CLOSED SURGICAL WOUNDS No. operations Bilateral phlebectorm'es 7 Cholecystectomy (with and without 5 common duct drainage) right subcostal incision. 3 Gastrectomy, linea alba ineision. 4 Exploratory laparotomy for regional enteritis with emaciatiou and partial mechanical obstruction, midline incision. 5 Hysterectomy; midline incision..-.-
. Breast biopsy (circum-areolar) 1 Inguinal herniorrhaphy Cecotomy for excision villous ade- 1 noma (right lower abdominal oblique). 9 Lipornectomy 1 10 Pilonidal cysyectomy 1 11 Small bowel resection for obstruct- 1 ing mesentric tumor metastic from pancreas (midline incision). 12 Abdominoperineal resection for 1 1 squamous cell carcinoma of anus (midline incision). 13 Ventral herniorrhaphy 1 14 Anterior resection of rectosigmoid 1 (midline incision). l5 Resection terminal 30 in. of ileum 1 1 proximal to ileostomy for regional ileitis', (reopening midline incision used fro previous total colectomy) l6 Lysis of adhesions and vagetomy 1 1 (midline).
Total operations. Total wounds- No wounds Type of operation In all 83 cases there was primary healing of all wounds except for intermediate suture abscess formation which was followed by healing without event. In none of these cases was there any abnormal liver chemistry, disturbed renal function, or evidence of sensitivity to the material of the invention. In no case was the wound non-flexible, thick or keloidal and all wounds appeared to be more flexible and less bulky than normally expected.
EXAMPLE 13 Calf tracheal cartilage powder having maximum particle size of 40 microns was mixed with about an equal part of anhydrous propylene glycol. This pre-mix was then added to Neobase (an ointment base made by Burroughs Wellcome & Co., of Tuckahoe, NY.) which contains the following ingredients: Glyceryl monostearate, Tween-61 (polyoxyethylene sorbitan monostearate), Span-60 (sorbitan monostearate), Paroleine (liquid paraffin), Propylene glycol, Methyl-p-hydroxybenzoate, Water (about 50% or more), diluted with about 50% additional water in an amount to yield a composition having about 10% of said powder.
Thus, a useful wound-healing or dermatological salve was formed, although it is to be understood that other ointments and salves and salve bases may incorporate the powder or extract of the present invention.
EXAMPLE 14 An ointment particularly useful with surgical gauze was formulated by mixing the following:
This ointment is useful in certain dermatological applications and the physical properties may be further adjusted and controlled by varying the ratios of the polyethylene glycols or adding required amounts of propylene glycol and/or glycerol.
While isotonic saline is an effective extraction medium, more complete extraction with higher healing activity is obtained when the pH is raised slightly with ammonia. Salts other than NaCl provide more effective extraction, as shown in Example 2. An inert atmosphere during the extraction results in extracts of greater potency than when the extraction is carried out in the presence of oxygen. Since the presence of oxygen during processing has completely inactivated extracts of the cartilages herein shown otherwise to be vastly superior, the use of suitable known non-toxic anti-oxidants such as ascorbic acid or its salts or vitamin A may permit carrying out the extraction in the presence of some air without serious loss of potency.
Though bovine tracheal cartilage from mature animals, i.e., a year old or older, is for some purposes a satisfactory source, cartilage with substantially greater potency is obtained from the skeletons of very young animals. The highest potency material is generally obtained from animals less than one month old, although cartilage from adolescent animals taken before maturity may be used in this invention Without excessively fine grinding. Young animals are intended to mean those which are still adolescent and have not yet reached maturity. Cartilage from foetal skeletons is often effective. Finely divided cartilage from other mammals, in addition to bovine and porcine and canine, is effective in healing wounds in accordance with the present invention: for example, finely divided cartilage powder from rat trachea and the human knee have been successfully utilized in accordance with the invention; so also with other animals such as the finely divided cartilage of birds, fish, jaw-bone of shark, rib cage of a crocodile (South American caiman known to be one year old, as obtained from the New York City Zoological Gardens, in early adolescence). Finely divided reptile cartilage is particularly effective in view of the extraordinary ability of the reptiles to regenerate their tissues and even their limbs. For example, young cartilage from the tail of a tegu salamander, which tail had regenerated for three months, obtained from the same zoo was used without excessively fine grinding in effective wound-healing experiments. Cartilage from the rib cage of young lambs taken prior to ossification was successfully utilized.
When dry cartilage extract is desired, freeze-drying is preferred, but spray-drying is satisfactory in inert atmosphere. Vacuum-drying is satisfactory when oxygen is excluded and temperature of the liquid is held below 40 C.
The cartilage powder may be dusted on the wound or atomized on it. It may also be applied in the form of ointment on the wound, as exemplified above. The extract may also be applied directly to the Wound by spraying it on the wound, swabbing it on, or brushing it on. Both the powder and the extract may be applied first to an absorbent medium which is then applied to the wound and held on by a bandage or adhesive tape, or other suitable means. The cartilage or the extract may be incorporated into tablets, capsules or suppositories and applied orally, rectally or in the vaginal or uteral passages. Implantation as pellets and injection of solution of the extract of the invention has been effective.
Cartilage extracts may be injected subcutaneously, intramuscularly or intravenously. The dried extracts may be used as powders or they may be reconstituted and used as the original extracts. The wounds to which the active materials are applied may be sutured or may be left open without materially aifecting the rate of healing. The active materials may be administered once, preferably within the first 24 hours of the incision; or they may be applied before the incision or they may be applied in several applications in succession. Irradiating the cartilage powder with ultraviolet radiation in the absence of oxygen increases its activity.
While certain present preferred embodiments of the invention have been described and exemplified herein, it is to be understood that the invention may be otherwise embodied within the spirit thereof and within the scope of the appended claims.
What is claimed is:
1. In a process of extracting an active wound-healing composition from cartilage powder which comprises contacting finely ground cartilage powder with a solution of an extraction solvent, the improvement which consists of the steps of (a) simultaneously extracting and grinding in a closed-grinding mill from which oxygen has been virtually excluded, to have an average particle size between about 1 micron and about 4 microns, and a substantial maximum particle size of about 70 microns, granulated defatted acid pepsin digested and essentially pure cartilage freed from adhering tissue, suspended in at least one aqueous extraction solvent selected from the group consisting of distilled water, isotanic saline solution, ammonia in water, urea in water, ammonium carbonate in water, trisodium phosphate in water, sodium citrate in water and sodium formate in water, having a pH between about 5 and 8, at a temperature of between 3 and 4 C., until a clear slightly opalescent aqueous cartilage extract can be obtained, and (b) spray-drying concentrate from such aqueous cartilage extract in a closed system hot gas atomizing spray drier, from which oxygen has been virtually excluded to avoid degrading the active material during the evaporation of the water, theinlet gas temperature held to about 280 F. and the outlet temperature between and F.
2. A process according to claim 1, wherein the extraction solvent employed is an aqueous solution of an alkali metal chloride salt.
3. A process according to claim 1, wherein the extraction solvent employed is an aqueous solution of sodium chloride.
4. A process according to claim 1, wherein the extraction solvent employed is an aqueous ammonia solution.
5. A process according to claim 1, wherein the extraction solvent employed is an aqueous urea solution.
6. A process according to claim 1, wherein the extraction solvent employed is an aqueous solution of an alkali metal phosphate salt.
7. A process according to claim 1, wherein the extraction solvent employed is an aqueous solution of an ammonium carbonate salt.
8. A process according to claim 1, wherein the extraction solvent employed is an aqueous solution of an alkali metal carboxylic acid salt.
9. A process according to claim 1, wherein the extraction solvent employed is an aqueous solution of a sodium citrate salt.
10. A process according to claim 1, wherein the extraction solvent employed is an aqueous solution of a sodium formate salt.
References Cited UNITED STATES PATENTS S. K. ROSE, Primary Examiner mow UNITED STATES PATENT OFFICE 56 CERTIFICATE OF CORRECTION 3,478,146 Nov. 11, 1969 Patent No. Dated Leslie L. Balassa Inventor) w It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
r" Column 3, line 39, change "weer" to --were--; lines 51- 52, change "disperaens" to "dispersions"; Column 5, line 6, change "strenght" to --strength--; line 12, change "oneet to ---cnset--;' line 14, change "laetx" to latex--; line 42, change "defererd" to --deferred-. Column 9, lines 25-26, for "co se'rved degree of granulation rea'd -coagulation. The rate of heating was measured by the observed degree of granulation-m Column 10, 7 line 17, lower the numeral "1" one space down, under headirqg- "No. operations and "No. wounds" to fall in line with Test 3 and Test 4; Test 10- in the description, change Wygmmwr to --cystectomy--; Test 11, change "me-centric to -mesenteric- Test 15, in last line of description, change "fro'f to -for-- Test 16, change "vagetomy" to -vagectomy--.
SIGNED m0 swan JUN 161970 mum; m a" n 055 I mmmem.
Oomissiom of Patents
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3318774 *||Jun 22, 1965||May 9, 1967||Squibb & Sons Inc||Treatment of osseous and other tissue|
|US3400199 *||Feb 26, 1965||Sep 3, 1968||Leslie L. Balassa||Wound-healing cartilage powder|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3966908 *||Jul 10, 1975||Jun 29, 1976||Lescarden Ltd.||Method of treating degenerative joint afflictions|
|US4216204 *||May 8, 1978||Aug 5, 1980||Robertson Harry J||Medical protein hydrolysate, process of making the same and processes of utilizing the protein hydrolysate to aid in healing traumatized areas|
|US4291013 *||Oct 9, 1979||Sep 22, 1981||Merck Patent Gesellschaft Mit Beschrankter Haftung||Medicinally useful, shaped mass of collagen resorbable in the body|
|US4347234 *||Jun 15, 1981||Aug 31, 1982||Merck Patent Gesellschaft Mit Beschrankter Haftung||Medicinally useful, shaped mass of collagen resorbable in the body|
|US4350682 *||Apr 4, 1980||Sep 21, 1982||Lescarden Ltd.||Cartilage extraction processes and products|
|US4486416 *||Mar 2, 1981||Dec 4, 1984||Soll David B||Protection of human and animal cells subject to exposure to trauma|
|US5618925 *||Feb 3, 1995||Apr 8, 1997||Les Laboratories Aeterna Inc.||Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof|
|US5733884 *||Nov 7, 1995||Mar 31, 1998||Nestec Ltd.||Enteral formulation designed for optimized wound healing|
|US5985839 *||Oct 8, 1996||Nov 16, 1999||Les Laboratories Aeterna Inc.||Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression: process of making thereof|
|US6025334 *||Oct 30, 1995||Feb 15, 2000||Les Laboratoires Aeterna Inc.||Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof|
|US6028118 *||Aug 8, 1996||Feb 22, 2000||Les Laboratoires Aeterna Inc.||Methods of using extracts of shark cartilage|
|US6168807||Jul 23, 1998||Jan 2, 2001||Les Laboratoires Aeterna Inc.||Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof|
|US6380366||Feb 15, 2000||Apr 30, 2002||Les Laboratoires Aeterna Inc.||Shark cartilage extract:process of making, methods of using and compositions thereof|
|US6383522||Sep 9, 1999||May 7, 2002||Les Laboratoires Aeterna, Inc.||Toxicity reduced composition containing an anti-neoplastic agent and a shark cartilage extract|
|US6506414||Dec 29, 2000||Jan 14, 2003||Les Laboratoires Aeterna Inc.||Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof|
|US6635285||Feb 7, 2002||Oct 21, 2003||Les Laboratoires Aeterna, Inc.||Shark cartilage extract: process of making, methods of using, and compositions thereof|
|US6855338||Feb 28, 2002||Feb 15, 2005||Les Laboratoires Aeterna, Inc.||Anti-tumor therapies comprising a combination of a cartilage extract and an anti-neoplastic agent providing high efficacy and low toxic side effects|
|US7951782 *||Sep 28, 2006||May 31, 2011||Maruha Nichiro Seafoods, Inc||Composition effective to prevent or treat adult disease|
|US8221500||Jul 24, 2008||Jul 17, 2012||Musculoskeletal Transplant Foundation||Cartilage allograft plug|
|US8292968||Feb 1, 2011||Oct 23, 2012||Musculoskeletal Transplant Foundation||Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles|
|US8435551||May 7, 2013||Musculoskeletal Transplant Foundation||Cancellous construct with support ring for repair of osteochondral defects|
|US8480757||Aug 28, 2006||Jul 9, 2013||Zimmer, Inc.||Implants and methods for repair, replacement and treatment of disease|
|US8497121||Mar 23, 2012||Jul 30, 2013||Zimmer Orthobiologics, Inc.||Method of obtaining viable small tissue particles and use for tissue repair|
|US8518433||Dec 15, 2011||Aug 27, 2013||Zimmer, Inc.||Method of treating an osteochondral defect|
|US8524268||Dec 15, 2011||Sep 3, 2013||Zimmer, Inc.||Cadaveric allogenic human juvenile cartilage implant|
|US8652507||Dec 22, 2010||Feb 18, 2014||Zimmer, Inc.||Juvenile cartilage composition|
|US8765165||Aug 23, 2010||Jul 1, 2014||Zimmer, Inc.||Particulate cartilage system|
|US8784863||Dec 22, 2010||Jul 22, 2014||Zimmer, Inc.||Particulate cadaveric allogenic cartilage system|
|US9138318||Dec 15, 2011||Sep 22, 2015||Zimmer, Inc.||Apparatus for forming an implant|
|US9347081 *||Apr 16, 2012||May 24, 2016||Bioiberica, S.A.||Cartilage product|
|US20040081703 *||Oct 17, 2003||Apr 29, 2004||Les Laboratoires Aeterna, Inc.||Shark cartilage extract: process of making, methods of using, and compositions thereof|
|US20050288796 *||Jun 23, 2004||Dec 29, 2005||Hani Awad||Native soft tissue matrix for therapeutic applications|
|US20100004182 *||Sep 28, 2006||Jan 7, 2010||Maruha Corporation||Composition effective to prevent or treat adult disease|
|US20100241228 *||Sep 23, 2010||Carina Syring||Engineered osteochondral construct for treatment of articular cartilage defects|
|US20110196508 *||Aug 11, 2011||Katherine Gomes Truncale||Cartilage repair mixture containing allograft chondrocytes|
|US20140113861 *||Apr 16, 2012||Apr 24, 2014||Bioiberica, S.A.||Cartilage product|
|USRE43258||Dec 13, 2010||Mar 20, 2012||Musculoskeletal Transplant Foundation||Glue for cartilage repair|
|DE2857532C1 *||Jun 12, 1978||Sep 15, 1983||Robertson Harry J||Therapeutisches Mittel zur Wundbehandlung und Verfahren zu seiner Herstellung|
|EP0302058A1 *||Jan 15, 1987||Feb 8, 1989||Lescarden Inc.||Method of processing animal cartilage and product produced|
|EP1021177A1 *||Feb 4, 1998||Jul 26, 2000||John V. Kosbab||Compositions and methods for prevention and treatment of vascular degenerative diseases|
|WO1980000059A1 *||Jun 12, 1978||Jan 24, 1980||H Robertson||Medical protein hydrolysate and process of using the same|
|WO1980002501A1 *||May 2, 1980||Nov 27, 1980||Lescarden Ltd||Cartilage extraction processes and products|
|Sep 17, 1982||AS02||Assignment of assignor's interest|
Owner name: CATRIX RESEARCH LIMIED PARTNERSHIP, 306 SOUTH STAT
Owner name: LESCARDEN LTD.
Effective date: 19820601
|Sep 17, 1982||AS||Assignment|
Owner name: CATRIX RESEARCH LIMIED PARTNERSHIP, 306 SOUTH STAT
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:LESCARDEN LTD.;REEL/FRAME:004037/0086
Effective date: 19820601